Login to Your Account

Dilution-Free is the Way to Be

Treximet Royalty Deal Padding Pozen's Coffers with $75M Cash

By Jennifer Boggs
Managing Editor

Tuesday, November 29, 2011
Pozen Inc. is beefing up its balance sheet by trading royalties for marketed migraine drug Treximet (sumatriptan/naproxen sodium) in exchange for $75 million in cash, a move the Chapel Hill, N.C.-based firm said will put it on solid financial footing as it starts partnering negotiations for PA32540, a gastrointestinal-friendly aspirin candidate in late-stage development.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription